Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-21 - Sofosbuvir, Velpatasvir, Voxilaprevir (Wirkstoffkombination)

Health, Health, Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

August 30, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Open House Original discount agreements 2025-21 - Sofosbuvir, Velpatasvir, Voxilaprevir (combination drug)

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyHealth, Health, Health
CountryGermany
CategoryPharmaceuticals
PublishedJuly 23, 2025
Procurement stageActive solicitation
Response dueAugust 30, 2027
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Verbandmittel
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Natalizumab (ATC-Code nach WHO: L04AG03)
Germany – Pharmaceutical products – Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2025-09
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Vareniclin (ATC: N07BA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen im Rahmen eines sog. Open-House-Modells zu diversen Röntgenkontrastmitteln (ATC-Code nach WHO: V08)
Germany – Pharmaceutical products – Arzneimittel-Rabattverträge ab 01.11.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Golimumab (ATC: L04AB06)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Denosumab, Handelsname Xgeva, ATC M05BX04

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.